Skip to main content
. 2016 Sep 1;7(40):66020–66031. doi: 10.18632/oncotarget.11791

Figure 3. Distribution of genomic patterns of resistance to anti-HER2 therapy.

Figure 3

Relevant mutations involve genes TP53/PIK3CA/MTOR/PTEN, all of which have been identified to correlate with resistance to anti-HER2 therapy. *Patient No. 6 displayed neither HER2 amplification nor specific mutations but we captured a mutation in RSP14 prior to progression which might be associated with treatment failure.